ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Donastas Sakellariou-Thompson
Matched on ORCID iD 0000-0001-5954-9557; OpenAlex author ID A5047829156. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 3
- Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
- Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-21-1248↗
- 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Milind M. Javle · 3 shared papers, 2017–2024 · strength 0.33
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Chantale Bernatchez · 3 shared papers, 2017–2024 · strength 0.33
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Shubham Pant · 2 shared papers, 2022–2024 · strength 0.28
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Ching-Wei David Tzeng · 2 shared papers, 2022–2024 · strength 0.28
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Michael James Overman · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Patrick Hwu · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Anirban Maitra · 2 shared papers, 2017–2022 · strength 0.17
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Rodabe Navroze Amaria · 1 shared paper, 2024 · strength 0.16
- Robert A. Wolff · 1 shared paper, 2024 · strength 0.16
- Amir Anthony Jazaeri · 1 shared paper, 2024 · strength 0.16
- Scott Kopetz · 1 shared paper, 2024 · strength 0.16
- Ying Yuan · 1 shared paper, 2024 · strength 0.16
- Matthew H. G. Katz · 1 shared paper, 2022 · strength 0.12
- Aislyn P. Schalck · 1 shared paper, 2022 · strength 0.12
- Michael P. Kim · 1 shared paper, 2022 · strength 0.12
- Gauri A Varadhachary · 1 shared paper, 2017 · strength 0.05
- Jianhua Zhang · 1 shared paper, 2017 · strength 0.05
- Ya’an Kang · 1 shared paper, 2017 · strength 0.05
- Timothy Paul Heffernan · 1 shared paper, 2017 · strength 0.05
- Vincent Bernard · 1 shared paper, 2017 · strength 0.05
- Jason B. Fleming · 1 shared paper, 2017 · strength 0.05
- Hector A. Alvarez · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.